Table 1.
Demographic and clinical characteristics of overall study cohort and according to quartiles of monocyte count
| Characteristic | Overall Cohort | Monocyte Quartile 1 >0.00 to ≤0.40 k/cmm | Monocyte Quartile 2 >0.40 to ≤0.55 k/cmm | Monocyte Quartile 3 >0.55 to ≤0.70 k/cmm | Monocyte Quartile 4 >0.70 k/cmm |
|---|---|---|---|---|---|
| No. (%) | 1,594,700 | 415,862 (26.1) | 382,263 (24.0) | 498,843 (31.3) | 297,732 (18.7) |
| Median monocyte count (IQR), k/cmm | 0.55 (0.40–0.70) | 0.40 (0.30–0.40) | 0.50 (0.50–0.50) | 0.60 (0.60–0.70) | 0.90 (0.80–1.00) |
| Median time from monocyte count to T0 (IQR), yr | 2.1 (0.6–3.6) | 2.1 (0.6–3.6) | 2.0 (0.6–3.6) | 2.2 (0.7–3.7) | 2.1 (0.6–3.7) |
| Race (%) | |||||
| White | 1,308,289 (82.0) | 312,045 (75.0) | 313,507 (82.0) | 425,010 (85.2) | 257,727 (86.6) |
| Black | 245,599 (15.4) | 90,462 (21.8) | 58,770 (15.4) | 62,491 (12.5) | 33,876 (11.4) |
| Other | 40,812 (2.6) | 13,355 (3.2) | 9986 (2.6) | 11,342 (2.3) | 6129 (2.1) |
| Men (%) | 1,512,680 (94.9) | 380,759 (91.6) | 361,818 (94.7) | 479,954 (96.2) | 290,149 (97.5) |
| Median age (IQR), yr | 62.0 (54.6–71.8) | 60.5 (53.2–70.9) | 62.1 (54.7–71.8) | 63.0 (55.2–72.2) | 62.6 (55.1–72.1) |
| Diabetes mellitus (%) | 456,591 (28.6) | 114,613 (27.6) | 108,237 (28.3) | 145,252 (29.1) | 88,489 (29.7) |
| Hypertension (%) | 1,087,788 (68.2) | 265,739 (63.9) | 257,155 (67.3) | 349,497 (70.1) | 215,397 (72.4) |
| Cardiovascular disease (%) | 502,250 (31.5) | 109,051 (26.2) | 115,026 (30.1) | 167,032 (33.5) | 111,141 (37.3) |
| Chronic lung disease (%) | 336,520 (21.1) | 70,301 (16.9) | 72,146 (18.9) | 110,466 (22.1) | 83,607 (28.1) |
| Peripheral artery disease (%) | 48,455 (3.0) | 9483 (2.3) | 10,350 (2.7) | 16,225 (3.3) | 12,397 (4.2) |
| Dementia (%) | 51,000 (3.2) | 13,141 (3.2) | 11,869 (3.1) | 15,756 (3.2) | 10,234 (3.4) |
| HIV (%) | 109,417 (6.9) | 28,482 (6.9) | 24,534 (6.4) | 33,164 (6.7) | 23,237 (7.8) |
| Hepatitis C (%) | 78,339 (4.9) | 20,929 (5.0) | 17,156 (4.5) | 22,899 (4.6) | 17,355 (5.8) |
| Cerebrovascular accident (%) | 8169 (0.5) | 1620 (0.4) | 1773 (0.5) | 2784 (0.6) | 1992 (0.7) |
| Hyperlipidemia (%) | 946,657 (59.4) | 233,221 (56.1) | 228,455 (59.8) | 306,461 (61.4) | 178,520 (60.0) |
| Cancer (%) | 202,957 (12.7) | 53,424 (12.9) | 47,192 (12.4) | 62,623 (12.6) | 39,718 (13.3) |
| Average eGFR at T0 (SD), ml/min per 1.73 m2 | 76.39 (18.7) | 77.68 (18.4) | 76.46 (18.5) | 75.59 (18.7) | 75.87 (19.5) |
| Median number of eGFR measures after T0 (IQR) | 12 (7–20) | 12 (7–19) | 12 (7–19) | 12 (7–20) | 13 (7–20) |
| Microalbumin-to-creatinine ratio (%),a mg/g | |||||
| 0–<30 | 88,187 (77.6) | 23,276 (79.3) | 20,513 (78.2) | 28,546 (77.4) | 15,852 (75.0) |
| 30–<300 | 21,792 (19.2) | 5297 (18.0) | 4899 (18.7) | 7087 (19.2) | 4509 (21.3) |
| ≥300 | 3617 (3.2) | 785 (2.7) | 819 (3.1) | 1229 (3.3) | 784 (3.7) |
| Median follow-up time (IQR), yr | 9.2 (8.3–9.4) | 9.2 (9.0–9.4) | 9.2 (9.0–9.4) | 9.2 (8.0–9.4) | 9.1 (6.5–9.4) |
| Death during follow-up (%) | 432,558 (27.1) | 94,039 (22.6) | 93,775 (24.5) | 140,676 (28.2) | 104,068 (35.0) |
k/cmm, 1000 cells per cubic millimeter; IQR, interquartile range; T0, time zero.
a
Numbers are for a subset of the cohort for which the corresponding data were available (n=113,596).